Last updated: 2026-09-05 23:57:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Longeveron Inc. (LGVN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $6,87, with a market capitalization of $21,62M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4,75 to $12,30. This page covers its latest market performance, valuation, price trends and company information.
$21,62M | |
$6,54 | |
$4.500,00 | |
$4,75 | |
$6,58 | |
39,31K | |
-- | |
-- | |
$12,30 | |
$4,75 | |
-- | |
-- |
Longeveron Inc. (LGVN) last closed at $6,58 as of 2026-09-04 23:31:00, unchanged from the previous close of $6,58.
During the latest regular trading session, LGVN traded between $4,75 and $4.500,00, with a volume of 39,31K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Longeveron Inc. (LGVN) moved from $6,75 to $6,87, representing a gain of 1,79% ($0,12).
The stock traded between $6,50 and $6,90 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 67,24 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 28,1%
LGVN is currently trading at $6,87, placing it 28,1% of the way from its 52-week low of $4,75 to its 52-week high of $12,30. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 38 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Longeveron Inc. (LGVN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.